Neumifil antiviral nasal spray developer Pneumagen has announced the launch of a platform called NeumoBind for intranasal protein formulations. The company says, “By anchoring proteins in place on a mucosal surface, NeumoBind addresses a critical challenge in mucosal drug delivery – rapid clearance – enabling enhanced residence time, longer-lasting therapeutic activity, improved efficacy, the potential for reduced dosing frequency and lower dosing.” According to the announcement, Pneumagen has initiated pre-clinical studies with “a selected therapeutic protein.”
In 2023, Pneumagen announced that a Phase 2 challenge study of Neumifil against influenza met its primary endpoint, and the company now says that it plans further clinical trials in patients with underlying conditions. Neumifil is “a multivalent, sialic acid-binding protein engineered from the Carbohydrate-Binding Module (CBM) of streptococcus pneumoniae neuraminidase A protein (SpCBM),” according to the web site.
Pneumagen CEO Douglas Thomson commented, “NeumoBind represents a major step forward in enabling the mucosal delivery of a wide variety of proteins. We believe there is considerable interest in our approach, and we are excited to explore partnerships with companies developing therapeutic proteins and antibodies that could benefit from mucosal delivery.”
Read the Pneumagen press release
